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Resumo Este relatório apresenta a minha experiência adquirida durante o estágio no
Centro de Investigação Clínica do Departamento de Neurologia do Hospital de
Santa Maria, simultaneamente com algumas atividades no Laboratório de
Farmacologia Clínica e Terapêutica e na Unidade de Farmacovigilância de
Lisboa e Vale do Tejo. O estágio realizou-se entre Setembro de 2013 e Junho
de 2014.
O estágio insere-se nas actividades curriculares do segundo ano do Mestrado
em Biomedicina Farmacêutica da Universidade de Aveiro.
Neste relatório irão ser abordadas as actividades de coordenação de ensaios
clínicos e estudos observacionais, bem como a descrição do processo que
levou ao desenvolvimento de uma revisão sistemática.
No decurso do estágio, tive a possibilidade de pôr em prática os
conhecimentos adquiridos ao longo do Mestrado, e aprofundar o meu
conhecimento sobre as actividades de coordenação de ensaios clínicos e
observacionais. Também tive a possibilidade de observar, ao longo do estágio,
todas as vantagens que existem em se realizarem ensaios clínicos num centro
de investigação mas também as dificuldades que estes centros enfrentam na
condução de estudos clínicos e observacionais.
No elemento de escrita científica, tive a possibilidade de ter instrução de como
desenvolver uma revisão sistemática, podendo assim executar uma
investigação.
Em conclusão, o estágio permitiu-me contactar com o quotidiano de um centro
de ensaios clínicos e pôr em prática o conhecimento adquirido na
Universidade, servindo ainda como nova fonte de aprendizagem, preparando-
me para o meu futuro profissional.
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Abstract This report presents my experience during an internship at the Clinical
Investigation Centre of the Department of Neurology at Hospital of Santa Maria,
together with some activities at the Laboratory of Clinical Pharmacology and
Therapeutics and at the Pharmacovigilance Unit of Lisbon and Tejo Valley .
The internship took place between September 2013 and June 2014.
The internship is part of the curricular activities of the second year of the
Masters in Pharmaceutical Biomedicine, University of Aveiro .
This report will address CT and OS coordinating activities, as well as the
description of the process that led to the development of a systematic review.
During the internship, I had the opportunity to put into practice the knowledge
acquired during the Masters, and deepen my knowledge of the coordination
activities of clinical and OS. I also had the opportunity to observe, along the
internship, all the advantages that exist in CT which are conducted in a
research centre but also the difficulties that these centres face in conducting
CT and OS .
Regarding scientific writing, I had the opportunity to be educated on how to
develop a systematic review, and thus perform an investigation.
In conclusion, the internship allowed me to contact with the daily life of CT
centre and put into practice the knowledge acquired at the university, still
serving as a resource for learning , preparing me for my future career .
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1. Introduction
Inserted in the second year of my Master’s degree in Pharmaceutical Biomedicine
(MPB), I applied and went through an internship at the Clinical Investigation Center
(CIC) of the Neurology Department at Centro Hospitalar Lisboa Norte, E.P.E. - Hospital
de Santa Maria (CHLN, E.P.E. – HSM) that had a duration of 10 months. Together with
the training at CIC, I had the possibility to spend some time in the Laboratory of Clinical
Pharmacology and Therapeutics (LCPT), workplace of most of the Clinical
Pharmacology Unit (CPU) team and in the Unidade de Farmacovigilancia de Lisboa e
Vale do Tejo (Pharmacovigilance Unit of Lisbon and Tagus Valley) (UFLVT). This
internship came in the sequence of one year receiving theoretical training in a wide set
of matters related with the drug life cycle such has Clinical Trials (CT),
pharmacovigilance and regulatory affairs. Later in this report I will give a more detailed
description of my training during this first year of my Master’s Degree. I had a special
interest in the area of CTs, so when I had the chance to have an internship in a CIC I
immediately applied for it, setting as primary objective to learn and practice as a Study
Coordinator (SC). During these 10 months of internship I was supervised by Professor
Joaquim Ferreira and Professor José Carlos Lopes. Along with the description of the
institution where I underwent my internship, in this document I present my activities,
learnings and projects over these 10 months.
In order to better describe my internship I divided my report in different chapters.
Along with this brief introduction, Chapter 1 is divided in two subchapters. In
subchapter 1.1 I discuss the history, structure and mission of my internship’s 3 hosting
institutions. These were the CIC, CPU and UFLVT. My background training in the 1st
year of my MPB and my internship objectives are described in the subchapter 1.2.
In Chapter 2 I describe some aspects about CTs namely in what they consist, which
are the different CT phases, how looks the current CT panorama in Portugal and,
finally, which and what are the responsibilities of the main regulatory authorities in CT
environment.
In Chapter 3 I describe the training that I received as well the activities that I performed
during my 10 months of internship giving a special focus to my training as SC.
In Chapter 4 I make a description of the projects that I developed in collaboration with
my colleagues from the CIC during my internship. These projects resulted in the writing
of review articles which are aimed for being submitted for publication.
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In Chapters 5 and 6 are presented the discussion of my internship as well as the
conclusions that I retrieve from my training, respectively.
The documentation and other resources that I consulted in order to help me to
construct this report are referred in References.
1.1. Vision about the host institutions
As referred before, my internship was carried in three groups: CIC, CPU and UFLVT. In
each one of them, different activities are performed but the professionals that work in
these 3 institution all cooperate with each other mainly due to the physical proximity of
these departments and because of the fact that some of these persons work in more
than one of these working places. These three institutions have their own history but at
some points they were and are related for the reasons mentioned before. At an
institutional level, the CPU actually contains the CIC and the UFLVT. The organisation
of these institutions is very recent so there are no literature references to that.
Information about its history is not very well documented too. The information that I
have about my hosting institution was in large scale available to me through verbal
contact with person responsible for these groups and well informed of its history and
current structure.
I will try to describe the history and the current panorama and activities of these three
organisations in order to better explain the environment where I trained during this
year.
1.1.1. Unit of Clinical Pharmacology
The LCPT is a physical space inside the Faculty of Medicine of the University of Lisbon
(FMUL) that aggregates some groups of the CPU. CPU is an institution from the
Instituto de Medicina Molecular (IMM) that comprises the Cochrane group which
belongs to an international collaboration network composed by institutions and
individuals intending to set new systematic reviews preparation standards, the CIC and
the UFLVT. From these the only group that is not located in the same physical local,
the LCPT, is the CIC as it will later be described.
Despite belonging to these different groups, the professionals that work at the CPU
collaborate with each other in order to maximize the efficiency of the work developed.
In general the groups collaborate in the CPU in order to produce investigator driven
15
research alongside with statistics, medical writing, project management and other
support activities. The current leader of CPU is Professor Joaquim Ferreira.
This institution, however, did not always have this structure. Long before the
appearance of IMM, a neuropharmacology section was created by physicians of the
movement disorders group, namely Professor Alexandre Castro Caldas, Professor
Virgílio Durão and Professor Cristina Sampaio.
Until 1967 it was difficult to get funding to research activities. The creation of Junta
Nacional de Investigação Científica e Tecnológica (JNICT - National Board of Scientific
and Technological Research) enabled financial support to research promoted by
institutions of higher education and postgraduates fellowships. In 1995 JNICT was
extinguished and was substituted only on a funding perspective by Fundação para a
Ciência e Tecnologia (FCT - Foundation for Science and Technology) during 1997(1).
FCT started promoting investigation from entities, research groups or individual
researchers that proved to have a strategy for scientific and technological development
inside Portugal(2).
IMM appeared in December of 2001 as a result of a fusion of efforts and activities from
the Portuguese Institute of Oncology Francisco Gentil and five former research units
from the FMUL.(3) Within these five research units could be found the “Lisbon
Neurosciences Centre”, group from where it was launched the bases to the team
where I developed my internship. It is located at the campus of the FMUL and is an
Associate Laboratory of the Portuguese National Ministry of Science, Technology and
Higher Education without any profit intentions. Its mission is to promote basic,
translational and clinical research in biomedicine. The ultimate goal is to contribute to a
better understanding of disease mechanisms allowing the development of new
predictive tests, improve diagnostic tools and more developed therapeutic
approaches(3).
It is possible to understand that through the years the financial support to the activity of
the pharmacology group raised gradually. As mentioned before the current leader of
CPU is Professor Joaquim Ferreira, which substituted Professor Cristina Sampaio, who
was the previous director of this team, when she left the unit to become Chief Medical
Officer of the Cure Huntington’s Disease Initiative (CHDI) Foundation. During the time
when Professor Cristina Sampaio was in charge of the this group, it was not yet known
as CPU but as Clinical Neuropharmacology Group (CNPG), a part of the Neurological
Clinical Research Unit (NCRU) from the group of Neurosciences, headed by Professor
José Ferro(4). Nowadays, under Professor Joaquim Ferreira work and with the
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constant broadening of the activities of the unit in addition to neurological research, this
unit became independent from that department, being only under IMM.
1.1.2. Clinical Investigation Centre
One of the subunits of the CPU is the CIC. Here I performed most of my work and
training during my internship. This unit is the only part of the CPU that is physically
present in the LCPT, being located on the 6th floor of the Neurology Department of
CHLN, E.P.E. – HSM.
Here is where CT and Observational Studies (OS) of new drugs for neurological
disorders and, sporadically, other interventional areas are conducted. Since a long
time, once Professor António Damásio and Professor Castro Caldas started integrating
clinical investigation, the hospital had CT in neurology but until 1999 there wasn’t a
specialized centre to receive these trials, which was implemented at that year by
Professor Joaquim Ferreira.
In the beginning of this unit, its main focus was movement disorders related CTs but
with time it started to receive more varied trials as it will be explained below. Until 2013,
this unit was known has the movement disorders group of the CNPG, under NCRU but
at that time, with the restructuring of CNPG and the change of its name to CPU, also
the unit where CTs were being performed adopted the name of CIC.
The CIC team is composed by full time 2 SCs and a lab technician that work together
with other health professionals such as physicians, nurses and the pharmacy team
depending on the CT staff requirements. Their responsibilities are well defined
according to ICH-GCP(5) and are presented below:
 Investigators are experienced clinicians which are qualified and trained
to conduct CTs. Since there are CTs in several different diseases like Familial
Amyloid Polyneuropathy (FAP), Alzheimer’s Disease (AD), Parkinson’s Disease
(PD) or Multiple Sclerosis (MS), for each of these diseases different clinicians
that work with the team assume the role of principal investigator (PI). During the
CTs, the principal or sub-investigators are responsible for the recruitment of the
participants, monitoring the patients during the CT by prescribing and controlling
study medication, ensuring its safety, keep in tract of any possible Adverse
Events (AE) and if necessary taking the decision of withdrawing the subject
from the study;
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 The SC is responsible for the entire logistic organization of the CTs
inside the CIC. Visits preparation, patient follow-up and its instruction about
study procedures are all under the responsibility of the SC. Additionally, it
performs Electrocardiograms (ECG) to patients, checks Vital Signs (VS),
processes biological samples, entries the gathered visit information in the Case
Report Form (CRF), answers queries, contacts with Clinical Research
Associate (CRA) handle financial aspects and oversee personnel, Summarizing
the SC is like the glue-guy in the research team;
 The laboratory technician has the responsibility of collecting biological
samples and processing them when applicable according with each study
protocol;
 The study nurses normally work has backups to the lab technician in
the task of collecting biological samples and also performs some specific
activities such has catheterizing patients in trials where there is Intravenous (IV)
medication or other needed support with the patients;
 The hospital pharmaceuticals are responsible for receiving, storing,
dispensing and accounting the investigational medical product (IMP). In our
specific cases, the prescription completed with the information obtained from
the Interactive Voice Response System (IVRS) or Interactive Web Response
System (IWRS) can be sent to the pharmacy by email and a pharmacy
assistant brings the IMP to the site. Then the investigator checks the batch
number and when it matches with the number obtained in the IVRS, the IMP is
delivered to the patient. Patients normally do not have to dislocate themselves
to the pharmacy to receive medication once has been established a
cooperation between the pharmacy and the rest of the research team. SC prior
to each visit alert the pharmacy of which medication will be necessary and a
carrier brings the medication to the site in order to deliver in to the subject. The
main reason for this special care is due to the fact that the research involves
patients with movement disabilities.
Since 1999, this unit as received according to records obtained in the centre 136
investigations, from which 104 are CTs and 32 are OSs. PD, Epilepsy, MS and AD
represent around 80% of the total investigations performed in CIC since its formation
but also trials in the area of FAP, Huntington’s disease (HD), Dystonia, Spasticity
between others can be found as illustrated in the graphic below. Note that in this
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graphic OS are all reunited independently of its focus disease, being only the CTs
divided in categories.
In the beginning of this decade FMUL, the CHLN, E.P.E – HSM and the IMM joined to
inaugurate a new institutional cooperation by creating the Lisbon Academic Medical
Centre (CAML). This consortium intends that through the fostering of translational
research, optimization of the use of resources either human or financial and by
improving the collaboration between research institutions at a national and international
level to give the best healthcare related products to consumers guarantying more years
of life and with better quality(6). From this collaboration resulted a new investigational
centre that is located at the 7th floor of the Neurology Department from the CHLN,
E.P.E – HSM which will be prepared logistically and will count with an experienced staff
in the area of CTs, composed in a part by the members of the CIC.
The name of the new units will be Centro de Investigação Clínica – Centro Académico
Médico de Lisboa (Clinical Investigations Center – Lisbon Academic Medical Center)
(CIC-CAML) and its objective is to receive CTs from all the medical specialties and
congregate in the same place all the clinical research activity of the CHLN, E.P.E –
HSM. This centralization will allow some benefits from which can be highlighted the fact
that the contact and the sending of documentation or medication between Pharmacy
and the CIC-CAML team well be easier than before, when the Pharmacy had to contact
with the all the different services that performed CTs. Additionally, the diverse staff
members that worked previously in different medical specialties related CTs are now
joining in the same group and can share their knowledge and strategies to improve the
efficiency of CT development. A high quality study centre will also be very useful to
Figure 1. Distribution of CIC’s CTs Number by Disease
Source: Records kept in CIC
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attract more CTs from industry increasing the investment an enabling possible future
investigator driven research.
1.1.3. Pharmacovigilance Unit of Lisbon and Tagus Valley
During my internship I spent 2 weeks in the unit of pharmacovigilance receiving general
training about its structure, the importance of its activity, what procedures there are
performed and which are the intended goals to reach annually by UFLVT. The activity
of pharmacovigilance units is very important in order to assure the safety on the use of
medication by the general population, since even knowing that the trials performed
during the drug development ensure the efficacy, safety and quality of the product, they
are performed in a small group of population when compared with the “real life” users
of the medicine and Adverse Drug Reactions (ADR) may occur at any time.
This unit is located in LCPT and is supported by Autoridade Nacional do Medicamento
e Produtos de Saúde (National Authority of Medicines and Health Products)
(INFARMED) being one of the 4 Pharmacovigilance Areas of the Portuguese
territories. In its area of influence, according to the 2011 Portuguese censos, there are
3659868 persons under UFLVT responsibility(7). It is responsible for processing ADRs
reports sent by health professionals and general public from the Lisbon and Tagus
Valley health region. With this and other procedures such as the promoting and
divulgating safety control methods like spontaneous notifications becomes possible to
monitor the safety of commercialized medicines(8, 9).
Additionally to this ADRs reception, UFLVT develops activities of training in order to
aware the healthcare professionals and general public of the importance of reporting
ADRs and explain how an ADRs is processed and which consequences and actions
may outcome from these notifications.  A periodic report about new ADRs is a part of
the UFLVT activities such has developing some epidemiological studies about the
Portuguese pharmacovigilance system(8, 9).
In the UFLVT work 4 professionals, one physician that is at the same time the head of
the UFULVT and the clinical coordinator, two pharmaceutics and one administrative
assistant. Each of them has their own responsibilities inside the UFLVT, contributing to
an efficient work of this unit.
1.2. Masters Background and Training Objectives
The years that I spent in University of Aveiro (UA) both during my Bachelor in
Biomedical Sciences and my first year of Master’s Degree in Pharmaceutical
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Biomedicine (MPB) were fundamental in order to have a high base of knowledge
especially in what refers to CTs. This would reveal to be fundamental for quickly fitting
into the clinical research team.
In my Bachelors, named Biomedical Sciences, I received a very widespread training
but I have to highlight what I have learnt in the fields of physiology, chemistry and
psychology because working on CTs required some skills that I got studying these
matters. Regarding my MPB, I had several different modules such has Non Clinical and
Clinical Development, Pharmacovigilance, Quality Systems, Regulatory Affairs, Project
Management, Statistics and Ethics(10). In all of these matters I received very important
information from highly qualified professionals which gave me an extensive set of
knowledge in order to be able to work in very different areas.
After this year I had to apply for an internship and my main area of interest was CTs. I
looked for opportunities of internship in this area having the doubt of either I wanted to
train as a SC or as a CRA.
I ended up choosing to apply for an internship as a SC trainee at CIC and I performed
an interview with Professor Joaquim Ferreira. I had the confirmation that I would be
accepted for my training still during April. Since I would start my internship only in
September I decided to gather all the information that I could about the centre. I
researched and spoke with my older colleagues from my Master’s Degree that
previously had trained at CIC. I got to know that in CIC they perform CTs in the area of
Neurology, that there works a multidisciplinary team and that when I would get there I
would be in close contact with both the patients and with study promoters, which
means Pharmaceutical Industry.
This led me to define some objectives regarding my internship even before I arrived to
the center as follows:
 Receive training in study coordination - I wanted to know which activities I
would have to develop in the future as a SC, what problems I would have to be
ready to face in this activity and what strategies can be adopted to face this
difficulties;
 Contact with the clinical research centre environment - With this I expected to
observe how the centre is managed in terms of delegation of functions to the
different healthcare professionals and what activities are performed in it;
 Apply all the theory lessons that I learned during my academic training over
CTs, inserted in my Master’s Degree, to the practice of study coordination.
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When I first got to the CIC I was informed that I would have the opportunity to work with
a multidisciplinary team. But at this point I could actually be presented to those persons
who promptly made themselves available to help me in whatever I needed and teach
me in their areas to help complementing my training. These professionals included
SCs, physicians, psychologists, nurses, laboratory technicians, pharmaceuticals,
statisticians and physiotherapists.
I was also informed that I would be able to work at the LCPT where several
investigations are performed as I mentioned before through systematic reviews and
meta-analysis and at UFLVT, where are processed almost all AEs notifications of the
zone of Lisbon.
Finally, when I first contacted with a CRA I verified how complex and important their
activity is to keep the quality and compliance with protocols of CT.
With this conjuncture I defined  some other objectives adding to the ones that I set
before coming to the clinical center. These additional objectives are:
 From contact with the previously refered healthcare professionals, obtain
theoretical and practical training ih their areas in order to make me a more
complete professional;
 Perform activities of researching and scientific writing at LCPT and receive
some on-the-job training about pharmacovigilance systems at UFLVT;
 Understand and lear how to develop monitoring procedures from contact with
CRA.
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2. State-Of-The-Art
My background training enabled me with a set of knowledge in the area of clinical
investigation that would reveal very helpful during my internship. There are some
concepts that anybody working in this area should be provided with.
2.1. Drug life-cycle
The clinical investigation, which was my main area of training during this year is
inserted in the medicines life cycle. I will briefly describe the different parts that
compose this cycle, giving a special attention to the clinical investigation phase.
In order to develop a new drug several stages and procedures have to be followed in
order to assess safety, efficacy and quality of the new molecular entity (NME).
2.1.1. Discovery
The first step is to discover a NME that possibly will originate in the future a new drug.
Thousands or even millions of molecules undergo a screening procedure with the
objective of founding to a certain biological target the correspondent lead.
A biological target is any structure or molecule, such as a nucleic acid or a protein,
within a living organism which is intended to be matched by some other entity. A lead
compound is a chemical compound that has a pharmacological or biological
activity likely to be therapeutically useful.
This action of inducing an interaction between a lead compound and a biological target
is intended to produce a therapeutic effect. After the identification of a potential lead
compound, this goes through a process of optimization and validation in order to
increase the probability of safety and efficacy of a future drug that can come from this
entity. A process of patent application is then followed in order to guarantee that a
potential new drug rose from this molecule or biological entity will not be developed by
any other research team(11).
2.1.2. Pre-clinical studies
After the patent is conceded, the IMP advances to the stage of pre-clinical
development where preclinical pharmacology and preclinical safety are assessed. This
studies are developed both in vitro an in vivo models. At this phase the in vivo models
are mammals such as rodents, dogs or monkeys. The species are selected depending
24
on the intended end of the research and which of the species, at the light of the current
knowledge is believed that can more precisely simulate the drug action inside the
human organism. The principal objective of the preclinical development of a compound
is to assess its safety profile(12).
2.1.3. Clinical development
The next stage is the clinical development where are inserted the CTs. I will focus on
this part because is my main area of interest and is my area of internship.
The concept of CT is relatively recent. In spite of that, several investigations were
performed and could be considered as a proto CT(13). The first registry of something
similar to a CT occurred when a British physician named Dr. James Lind designed and
controlled in 1747 the first clinical investigation. For this he is called the father of CTs.
He performed an investigation with 12 sailors when he was serving as a surgeon in a
British naval ship. The objective was to assess why there was such a high mortality
due to scurvy. He divided the 12 subjects with the same symptoms in 6 groups of 2and
giving them 6 different scurvy treatments in addition to their normal diet: either cider, a
weak acid, vinegar, sea-water, nutmeg and barley water, or oranges and lemons.
Oranges and lemons proved to give the best results(13, 14).
Nowadays, CTs are much more complex and have a regulated definition. In the page 9
of ICH-GCP can be found that a CT is “any investigation in human subjects intended to
discover or verify the clinical, pharmacology and/or other pharmacodynamic effects of
an investigational product(s), and/or to identify any adverse reactions to an
investigational product(s), and/or to study absorption, distribution, metabolism, and
excretion of an investigational product(s) with the object of ascertaining its safety
and/or efficacy”.  CTs can be classified either according to a sequential classification of
the phases (from phase I to IV) or according with the objective: human pharmacology,
therapeutic exploratory, therapeutic confirmatory and therapeutic use. The two
classifications can be related to each other having some king of transposition but since
one trial may occur in different temporal phases it is more correct to classify them
according to the objective(15).
CTs can this way be divided as follows:
 Human pharmacology trials are usually identified with Phase I studies.
These first-in-human trials of a new potential drug are carried out in healthy
volunteers or in restricted groups of patients. The objectives are assessing the
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tolerance, describing the pharmacokinetics and pharmacodynamics profiles of
the drug, exploring the drug metabolism and interactions, and estimating the
activity of the drug. Some examples of these studies are dose-tolerance
studies, single and multiple dose Pharmacokinetics and/or Pharmacodynamics
studies and drug interaction studies.
 The therapeutic exploratory studies are linked to Phase II studies and
are normally conducted in reduced groups of patients. Its primary objective is to
explore the therapeutic efficacy in subjects with the intended disease to treat.
These studies are aimed to explore the use of the drug for the targeted
indication, to estimate the dosage for the subsequent studies and to provide the
basis for confirmatory study design, endpoints and methodologies. Some study
examples are earliest trials of relatively short duration in well-defined narrow
patient populations, using surrogate or pharmacological endpoints or clinical
measures and dose-response exploration studies.
 Therapeutic confirmatory studies, which are normally related with Phase
III trials, have as primary endpoints to demonstrate or confirm the efficacy of the
drug, to establish a safety profile, to provide an adequate basis for assessing
the benefit/risk relationship to support licensing and to explore the dose-
response relationship. Some examples of these studies are adequate, and well
controlled studies to establish efficacy, randomized parallel dose-response
studies, clinical safety studies, studies of mortality/morbidity outcomes, large
simple trials and comparative studies.
 Therapeutic use studies or Phase IV studies begins after the drug
approval. These studies have as objectives are to refine the understanding of
the benefit/risk relationship in general or special populations and/or
environments, to identify the less common adverse reactions and to refine the
dosing recommendation. Examples of studies are comparative effectiveness
studies, studies of mortality/morbidity outcomes, studies of additional endpoints,
large simple trials and pharmacoeconomic studies(15).
Apart from CTs, there are other studies involving humans known as OSs. In these
studies there isn’t any pharmacological intervention, being based only in assessing
health outcomes in groups of patients in accordance with an established protocol or
research plan.  Interventions received by participants in OSs must be related with their
normal clinical practice and not with any particular therapy strategy involved with the
research objective.  Participants should not, as well, be submitted to any additional
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evaluations. Data collected, thus shall be analyzed by epidemiological methods(16,
17).
2.1.4. After commercialization
After proving its efficacy and safety, new potential entities can be proposed for a
marketing authorization, and if approved can enter the market. After being
commercialized, together with the normal therapeutic use trials that were mentioned
before, there is a constant vigilance in order to detect, assess, understand and prevent
adverse effects or any other drug-related problem. This process is known as
Pharmacovigilance(9, 18).
2.2. Regulatory Authorities
The area of drug development and particularly the CTs are widely regulated. In order to
better understand this regulatory environment, a brief description of some institutions is
given:
 International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH) is a combined initiative
between regulatory authorities and the pharmaceutical industry from United
States, Europe and Japan. Its goal is to discuss scientific and technical aspects
of drug registration. By harmonizing the regulatory processes and obligations it
ensures that safety, effectiveness, and high quality standards are applied in
Figure 2. Clinical Development Phases
Source: Figure 1 of Reference 15
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new medicines development and that its registering is carried in the most
resource-efficient manner(19);
 European Medicines Agency (EMA) is the regulatory agency of the European
Union (EU) essentially responsible for protecting and promoting public and
animal health. This process is executed by evaluating and supervising
medicines for human and veterinary use. An important duty of EMA is to
evaluate scientifically the applications for EU marketing authorizations. In what
concerns safety and benefit-risk balance of medicines to be or already
approved by a non-centralized procedure it assumes an arbitrary position. It
also monitors the safety of medicines by the establishment of a wide
Pharmacovigilance network and stimulates the continuous research
improvement in pharmaceutical area(20);
 Food and Drug Administration (FDA) is the United States of America’s agency
responsible for protecting and promoting public health. The processes that lead
to that end are reached by regulating and supervising food safety, tobacco
products, dietary supplements and pharmaceutical products(21);
 INFARMED is a public institute included in the indirect administration of the
State. This signifies that INFARMED is endowed with administrative and
financial autonomy and has its own patrimony. INFARMED IP is a central body
with jurisdiction over the entire Portuguese territory and acts by regulating and
supervising the areas of drugs, medical devices, cosmetics and personal
hygiene products according with the highest standards. Is mission is to protect
public health and ensure access to health professionals and citizens to
medicines, medical devices, cosmetics and personal hygiene products with
quality, effectiveness and safety;
 Comissão de Ética para a Investigação Clínica (Portuguese Ethics  Committee
for Clinical Research) (CEIC) is an independent organism with the participation
of different professionals connected or not with the healthcare activity which
aims to guarantee the protection of the rights, safety and well-being of the CT
subjects, by emitting an ethical opinion over the submitted research protocols.
Also monitors Health Ethics Committees, receiving all applications for ethical
review(22);
 Comissão Nacional de Proteção de Dados (Data Protection National Comitee)
(CNPD) is an independent administrative entity with authority powers. Its
function is to control and supervise the data processing always in compliance in
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a rigorous respect for human rights and freedoms according to Portuguese law
and constitution(23);
 The Council for International Organizations of Medical Sciences (CIOMS) is an
international, non-governmental and non-profit organization recognized
mutually by WHO and UNESCO in 1949. It has the purpose of helping in the
reach of scientific goals of the international biomedical community in general
and its specialized agencies. This is done by facilitating and promoting
international biomedical sciences activities and working on the relations of the
science community with the United Nations(24);
 International Organization for Standardization (ISO) is an independent and non-
governmental organization constituted by representatives of the national
standards bodies of 164 countries. Its aim is to help on simplifying the
coordination and unification of international industrial standards(25);
 Associação Portuguesa da Indústria Farmacêutica (Pharmaceutical Industry
Portuguese Association) (APIFARMA) founded in 1975, represents more than
120 portuguese companies responsible for Production and Import of Medicinal
Products for Human and Veterinary Use, Vaccines and Diagnostics In Vitro with
a view to solving common problems, the socio-development economic sector of
the country and the improvement of health in Portugal and greater patient
access to new therapies(26).
2.3. CT Regulatory Framework
Behind the practise of CTs there is a very widespread set of regulatory documents that
serve as guidelines to the conduction of these research procedures either concerning
medical aspects and ethical considerations. From these set of documents some can be
highlighted due to its importance and transversally across all the CTs. The following list
of guidelines and declaration is the base for the work of all the healthcare professionals
within CTs.
2.3.1. Worldwide Documents
 In 1947 the Nuremberg Code was elaborated in answer to the atrocities
committed during World War II, specially the medical experiments conducted in
concentration camps by the Nazis where prisoners were tested without any kind
of agreement. These experiments led to deaths and disabilities in thousands of
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human beings. The principal aspect of the Nuremberg Code is the demanding
that all CTs performed in a person must have his informed consent form
(ICF)(27);
 The Helsinki Declaration appeared in 1964 in answer to the Thalidomide
disaster in which thousands of babies born with abnormalities due to lack of
knowledge about secondary effects in pregnant women when taking that drug.
This declaration specifies a series of ethical principles for medical research
involving human subjects in CTs. It suffered 10 amendments seven times since,
with the last one having occurred in 2013, adopted at WMA General
Assembly(28);
 The ICH-GCP E6 is a document which final version was issued in 1996 and
intends to standardize clinical research in all three ICH regions: the United
States of America, Europe, and Japan. Responsibilities of each participant of a
CT, specifically the sponsor, the investigator and the CT coordinator amongst
many others are described in this document(5).
2.3.2. European Legislation and Portuguese transpositions
 Directive 2001/20/CE, April 4th, also called the CT directive, specifies the
requirements for the conduct of CTs in the EU. This directive was transposed
into the Portuguese national law by the Decree-Law 46/2004 of August 19th(29);
 Directive 2005/28/CE, April 8th, lays the principles for Good Clinical Practices of
experimental drugs for human use. This directive was transposed into national
law by the Decree-Law 102/2007 of April 2nd(30);
 Directive 95/46/CE, October 24th, concerning the protection of patient data. This
directive was transposed to national law by ordinance nº 67/98 “Personal data
protection” and by Resolution nº333/2007 and this one regards personal data
protection in CTs with medicines for human use(31).
Following the idea that all healthcare professionals working on CT must be familiarized
with these documents, during my training in University I recurrently had references to
these guidelines and I ended up applying them coming into this internship.
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2.4. Clinical Investigation in the world
With a constant need of developing new medicines and acquire knowledge about the
existing ones, CTs and OSs are increasing in number in a large scale. One of the
sources that state this situation is ClinicalTrial.Gov that by the date of 3rd June 3, 2014
“lists 168,182 studies with locations in all 50 states and in 187 countries.” This numbers
show the incidence of research in the medicines area. This database also provides
some data about specificities on these total numbers. It is stated that almost 80% of
investigation worldwide are CTs and the remaining 20% are OSs. Considering the type
of intervention, 53% are drug or biologic interventions, 21% have a behavioural
directed study, 9% are related with surgical procedures and 8% are related with
medical devices. Attention to the fact that each CT may have more than one type of
intervention and that’s why if we add the sum of all the categories the result won’t be
the percentage of CTs(32).
The numbers of registered and recruiting studies sorted by region are presented in the
table below.
Table 1. Number of Worldwide Registered and recruiting Studies (32)
Location
Number of Registered
Studies and Percentage
of Total
Number of Recruiting
Studies and Percentage
of Total
Non-U.S. Only 75,868 (45%) 16,716 (51%)
U.S. Only 67,403 (40%) 14,211 (43%)
Not Specified 14,662 (9%) -------------------------------
Both U.S. & Non-U.S. 10,249 (6%) 1,963 (6%)
Total 168,182 (100%) 32,890 (100%)
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Over the years, the number of CTs increased. The figure below gives an idea on the
much bigger dimension of the investigation nowadays when is compared, for example,
with the beginning of the millennium. From 2000 to the present date we went from
having 5635 investigations worldwide to 159207(32).
Having this general numbers presented, it’s now important to compare these results
with the ones from Portugal and so the next subchapter is dedicated to give a view of
clinical investigation in our country.
2.5. Portuguese CT Panorama (33)
When we compare the incidence of CTs in the Portuguese territory with the ones from
Europe or even in the rest of the world, we notice that there are differences in the
number of centers, participants and money invested or profited. This may be explained
by how small our country is compared with other countries that perform much more.
Other reasons can be pointed for these discrepancies. It is important to analyze the
data and find the pros and counters of how clinical investigation is performed and
supported in Portugal.
Figura 3. Number of Registered Studies (2000-present)
Source: ClinicalTrials.gov. Trends, Charts, and Maps 2014 (32)
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Most of CTs performed in Portugal are promoted by R&D multinational enterprises.
During the year of 2012, indicators show that these enterprises invested in CTs in
Portugal a total of 36 million euros. This investment contributed to savings in the order
of 3.5 million euros in what it comes to public spending in drugs and complementary
diagnostic procedures. In the same year 1086 workplaces were dedicated directly to
CTs and these studies were responsible for a global Gross Value Added of 72 million
euros. For each euro invested it is estimated that there is a return of 1.98 euros,
making this area one of the more profitable of the country.
In spite of this good economic values, Portugal does not take everything that it could
from CTs. In fact, being the CTs one the main indicators of the interest in innovation
and investigation in health, the reduction of the number of CT in Portugal shows how
we are losing competitiveness in a progressive and alarming pace.
A recent study conducted in joint by Pwc and APIFARMA in 2013 gave a clear image
of the actual panorama of CT in Portugal(33).  According to this report, the number of
CT submitted in Portugal from 2006 to 2012 fall an impressive 26%, going from 160 to
118 studies. Actually, in 2011 it was verified the lower number of CT registered since
2006, only 88 studies. Concerning authorized CT the number has gone from 147
(2006) to 99 (2012) having the lower number been reached in 2011 as well, 87 studies,
a drop of 33%.
It is not easy to invert this trend. To increase Portugal’s competitiveness in the
enrollment of new CT some measures needs to be established. One of the things that
are influencing the loss of competitiveness comparing with other European countries is
the average time that a CT takes to be approved. This approval time lasts since the
submission of the initial approval request and the reception of the last regulatory entity
approval and in 2012 it was of an average of 70 days. The aggravating of this numbers
is that these 70 days do not include the time that the hosting institution takes to
approve a trial. If we add this time to the already more than 2 months it can rise to
more than 6 months from average time to approve a CT.
Inefficiency and uncertainty clarification requests, absence of legal deadlines for
approval of the financial contract, and a mandatory approval by the National Committee
for Data Protection without legally stipulated deadlines also hurt Portugal’s
competitiveness. From 2009 to 2012 the average percentages for each phase of CT
was of 2% for Phase 1 studies, 18% for Phase 2, 70% for Phase 3 and 10 % for Phase
4. This shows the importance of phase 3 studies in Portuguese clinical research.
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This report also stated approximately 98-99% of CTs are held by international
promoters and 94% of trials in Portugal are promoted by the Pharmaceutical industry
and only 6% was held by academic institutions in the year of 2010, mainly due to the
lack of legislation regulating and promoting academic research. This last indicator
differs in great scale from countries like United Kingdom and Spain, where academic
investigation represents something like 25% of the total studies.
Continuing to compare Portugal with other countries, in this case, with ones that
present a similar number of inhabitants such has Austria, Belgium and Czech Republic
we can observe that we are far below from the other countries as is shown in the table
2. These values were obtained by APIFARMA in a survey realized in 2009 that got
information about CTs conducted by ten pharmaceuticals in Portugal and comparing
them with the previously referred countries. This numbers is alarming since Portugal is
losing money because the lower number of trials implies less money being applied in
the country.
Table 2. Portuguese CTs expression compared with size equivalent countries
(33)
Country Number
of active
CTs
Number
of
planned
sites
Planned
patient
recruitment
Investment
(in millions
of euros)
Portugal 147 461 3.917 58,755
Austria 188 596 5.602 97,530
Belgium 328 1.024 12.996 194,940
Czech
Republic
218 967 15.433 231,495
Patient recruitment lack of efficiency is another factor that is slowing the entry of money
in Portugal from CTs. According to another APIFARMA survey conducted from 2007 to
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2011, in a universe of 443 trials, sensitively 14 million euros were lost due to failed
patient recruitment.
Facing all of these indicators it’s obvious that there is room to develop the efficiency of
CTs in Portugal in order to get a better profit. There are some main obstacles that shall
be faced in order to fulfil that: Politics and Strategy; Policy and Legislation;
Organization and Infrastructure; Incentives and Training; Technology and information.
The transposition of the current European Directive for CTs is seen as one of the more
important factors to the lack of efficiency in this are in EU especially in some countries
like is the case of Portugal. Promote communication between stakeholders and
recognize the window of opportunity that was created by the last review of the UE
legislative network in March 2014. A turnaround in this trend could bring a lot of
benefits, especially financial, to Portugal such has:
 Contributing to the budget of the state through paid taxes.
 Providing alternative cost savings.
 Being an additional mechanism of remuneration to investigators.
 Creating employment opportunities with additional work for researchers and
young physicians
 Raising economic stimuli for other supporting business.
 Giving improved access for patients to better treatments (a patient under a trial
has a more intense monitoring than one that is out of any trial);
 Generating knowledge sharing and transfer of new technologies.
This panorama got me very excited to work in this area and I expect that with my work,
I can somehow help to the evolution
2.6. Overall CT stages
To give a clearer idea of how a CT is conducted and which are the regular procedures
since the idea of performing a CT until its end and presentation of its results I will give a
brief description of it.
2.6.1. Feasibility assessment
The birth of any CT in a research center results of a sponsor, academic or from the
industry, wishing to perform an investigation. At a national level, the sponsor evaluates
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if is feasible to implement a trial according to the number and conditions of the centers
that are willing to receive the trial.
After passed this general evaluation phase, it is checked the feasibility inside each
center. During this process is checked if the site is adequate to receive a trial in terms
of facilities as well as if it has an experienced and qualified staff depending on what the
trial demands, if the site has access to a patient population that can be enrolled and if
the healthcare professionals of the site are really interested in performing the study.
Most of times, this involves a questionnaire to be filled by the PI with the help of the
SC. As a part of this phase some meetings between the representatives of the sponsor
and the PI and SC occur. The objective of these meetings normally are discussing the
number of subjects that the site is willing to enroll, which barriers most likely will appear
to this study and also the financial agreement is discussed. With an affirmative ending
to all this conversations and procedures, the center becomes eligible to enter the study
After the assessment of feasibility, submission to the administration board and to the
ethics committee has to be performed. If the trial is approved the center is eligible
either in the point of view of the promoter as well as by the hosting institution.
2.6.2. Investigators meeting and Site Initiation Visit
The next step is performing a investigators meeting where there is a training on the
study protocol and ICH-GCP (5) to all participants including CRA, SC, Investigators,
medical monitors, quality assurance professionals and senior management.
After the investigators meeting, a study initiation visit is performed. During this visit,
representatives from the sponsor come to explain in what consists the trial to the
healthcare professional that will perform the study in the site. Any question that exists
about the study design and procedures or any other detail shall be recalled in this
meeting. After this meeting the enrollment of patients may begin.
2.6.3. Study phase
Before any patient is enrolled to the study, he must be informed about everything within
the scope of the trial by one of the investigators of the study. At the same time a copy
of the informed consent is delivered to the patient so he can read and be clarified about
study procedures, study drug information, safety concerns, ethical and financial
considerations between other matter in order to take a conscious decision about
entering or not in the study. If he manifests his will in entering the study it is appointed
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a visit with the PI in order to both sign the inform consent, indicating that the subject
agrees to ponderously enter the trial. Once the Informed Consent is signed, the next
step is scheduling the Screening Visit.
In the screening visit the patients is asked about him, familiar history and performs
some exams in order to check if he fits all the inclusion and exclusion criteria. If he
does fit the criteria, the patient advances to the baseline visit. In this phase if the trial is
randomized with more than one arm in its study design, the patient is allocated to one
of the treatment arms, which can be, depending on study design, a dosage of the study
medication, an active comparator or a placebo.
After its randomization the patient enters the treatment period of the study which can
last from a few months to some years depending on the application of drug that is
being tested and on study design. For example normally medicines for chronic
diseases need longer trials then the remaining and phase III trials are longer than
phase II. In this treatment period regular visits to the site are performed in order to
follow the patient looking for AEs, checking his willingness to continue in the trial, drug
accountability and perform many other medical procedures considered in the study
protocol. All the data collected in these visits shall be registered.
If the patient reaches the end of the trial he can enter in an open-label follow-up of the
study or he can receive the drug by compassionate use if not entering a new study.
The first situation is directed to people that where involved in blinded investigations. In
the case of blinded CTs, after the investigation is over the subject may enter an
extension phase in which he knows that he is taking the medicine. Normally patients
opt on this when the previous results about the study medicine are good and there is a
trend to believe it is really beneficial. Compassionate use is the usage of a still not
marketed and authorized medicine. This program of prescription is dedicated for
patients of the EU without a satisfactory authorized therapy to their disease and cannot
enter a CT.
Sometimes, the patient may not reach the end of the study for any reason such as
simply don’t want to be a part of the study anymore, stop fitting the study criteria, taking
prohibited concomitant medication, a serious AE happening with causality attributed to
the study drug or a female participant might become pregnant or the participant death.
The patient safety is always in first place so if there is anything that can put its life in
danger within the scope of the CT, he is immediately discontinued of the study.
The SC is present in every stage of this process being an essential member to
guarantee that the study is well coordinated and documented and by helping the entire
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research team. I had received training during my internship to be able to perform my
activities in each of the phases as a SC. That training together with other experiences
and projects will be referred below.
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3. On-the-job training
During my internship my main focus of training and practise was in activities related
with CTs coordination. Apart from this area of training I also had the chance to go
through some monitoring activities, assist and participate in the preparation of an audit,
develop systematic reviews, being familiarized with practical pharmacovigilance
procedures and quality systems and  have some extra theoretical training in diverse
areas. I describe those activities below.
3.1. Disclaimer
Before I continue describing my internship activities I want to alert that being a part of a
CIC I had to, in the beginning, sign a confidentiality agreement concerning the sensitive
and confidential information that I would manage working as a SC trainee. Study
protocol and investigator’s brochure information along with the participant’s data are
some of the material that I cannot share. I can, anyway, share information that is of
public access such as the trials names and general information about the trials and as
well describe what I have learned during my training as SC.
3.2. Timeline of my internship
During my internship which lasted between September 2013 and June 2014, I spent
most of my time assisting has a SC. Actually, that happened because my biggest
objective coming to this internship was to be in contact with clinical studies
coordination. When I have arrived to the center in September 2013 I was introduced to
the CTs that were part of the CIC set of active studies. From 9th to 20th December,
2014 I was in UFLVT and I was trained on the usual processes taken from the moment
of the receiving of a notification to its imputation of causality and which consequences it
may have. At the same time I had the possibility to study the UFLVT quality system.
That was very useful because it was the first time that I contacted with a complex
quality system in a professional environment. After these 2 weeks I returned to the CIC
where continued my training as SC. In March I was challenged to start performing
some research in order to do a systematic revision. I took part of 3 investigations and in
one of them I was the PI. In the latest months of my internship together with the
support that I gave in all the clinical center studies I was assigned to an Alnylam CT in
Familial Amyloid Polyneuropathy (FAP) named ALN-TTR02-003 with the role of SC.
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Figure 4 - Timeline of my internship
3.3. Arrival at the internship organization
In my first day of internship I had a meeting with my internship supervisor Professor
Joaquim Ferreira in order to define in which area of the UFC I would primary be
allocated to. Since my main objective coming into to the internship was to have training
in study coordination, Professor Joaquim Ferreira suggested that I stayed mainly at
CIC. In my first week there, I spent most of my time getting familiarized with the
structure and operations of the center and with my colleagues of the research team in
order to be able to cooperate with the rest of the team, once the SC role is in the center
of the all CT related activities. The group is composed by professionals with different
backgrounds and different roles within the team. It the center collaborates at full time
two SCs, Ana Noronha and Maria Finisterra and a laboratory technician, Antonieta
Alves Apart from those, also a group of physicians, which are the studies’ investigators,
psychologists, study nurses and pharmacists, also give support to the CIC CT.
3.4. Study of Regulatory Literature
Before I started to get involved in CTs procedures I had to restudy the literature that
regulates and gives orientation to clinical investigation. The bibliography regulatory
documentation that I described in Subchapter 2.3. “CT Regulatory Framework” was the
main support to my training in terms of general knowledge about regulatory
considerations.
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3.5. CT Essential Documents
After having a close knowledge of the regulatory documents in which clinical
investigation resides its orientation my theoretical training was yet not over. Before I got
in direct contact with the different CTs and running its related procedures, I had training
about them through the study of its documents and procedures. I had contact with the
CT Protocol, Informed Consent Form, Investigational Product, Subject’s diaries, AE
and Serious Adverse Event (SAE) reports, Investigator Site File (ISF), CRF, Source
Documents (SD), Monitoring requirements and Central Laboratory. Details about each
of these matters will be later described. This early theoretical training was very
important on helping me to perform my job properly in the different trials.
3.6. Study Coordination Specific Training
Concerning my specific activities in study coordination I was introduced by my
colleagues of CIC to the procedures that I would have to perform as a SC across the
different phases of each CT. I participated In the processes of more than 10 CTs and in
five OSs. Each of them had different protocols with different procedures to be followed
and executed. In spite of that most of the things that a did across the different studies
can be matched.  I will describe the training that I had and the tasks that I developed
during this year of internship, which are intimately related to the activity of a SC. For
that I will divide this description by the different CT stages as explained in subchapter
2.6.
3.6.1. Attending feasibility and investigators meetings
During my internship I had the opportunity to assist to the feasibility assessment of CIC
for 3 different CTs. I was present during some meetings between CRAs and other
representatives from the promoter and members of the CIC, namely each CT PI and
the SCs. I had the chance to get contact with the matters that are discussed during this
meeting such as the financial agreement, some doubt clarification about the study
requirements, the definition of how many patients would be included and the discussion
of some barriers that predictably may appear during that CT. I was instructed about
what are some of the SCs tasks during this phase that are specially directed to the
interaction between the sponsor and the administration board and the ethics committee
and by obtaining and submitting all the necessary documentation prior to the
acceptance of a CT in CIC.
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I did not have the chance of attending to any investigators meeting but my colleagues
SCs shared with me the importance of the presence in the reunion of either the study
PI and the SC once in these meetings they are trained on the protocol and procedures
and important comments with the objective of improve the CT design or processes are
made.
3.6.2. Site initiation visit
I had the opportunity to attend to site initiation visits from three different trials. The
importance of these meeting has already been referred in subchapter 2.6.2.  After
attending to these meetings, normally I would together with my colleagues SC and the
sponsor CRA gathering a list of necessary documents for being signed such has the
delegation log, the study initiation visit signature page or CVs not yet delivered by the
professionals involved in the referred CTs.
3.6.3. Online and by telephone trainings
Before it is considered that a SC or any other participant in a CT is enabled for doing a
procedure, he has to go through training. This can be performed by watching an online
training which normally as a final evaluation to assess the professional’s capability to
do the procedures or by attending to an interactive teleconference in which is explained
by a promoter representative everything about the tasks delegated in each person. I
had the possibility to view or assist by several times to these trainings or
teleconferences. These trainings included matters like the Electronic Case Report
Form (e-CRF), ICH-GCPs (5), IVRS/IWRS, samples shipment, ECGs and VS and the
screening and randomization process.
3.6.4. Patients visits
After the site initiation visit patients may start to be included. The activities in which I
was trained as a SC during this phase can be divided on the ones that are performed
before, during or after the subjects’ visits as is explained below.
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3.6.4.1. Prior to the visits
The first thing to do in order to prepare a study visit is scheduling it with a patient. I was
trained on how to contact with patients depending on their limitations in order of clearly
transmitting all the needed information.
When the visit day was coming I would look to the study flowcharts in order to see
which procedures would have to be performed. In some studies I also prepared my
own checklists and worksheets in order to better organize the upcoming study visit.
This was important because each study visit has an order of procedures that shall be
followed and in addition to that of them some can take a lot of time if not planned
properly. Elaborating these checklists can make easier the investigators and raters job
and at the same time reduce the duration of the consults avoiding a high burnout for
the patients.
I would then gather and prepare all the needed material. In this material is included
patient’s medical record, CRF/Patient’s binder, study kits, IVRS worksheets, EGC
readers, patient’s diaries, questionnaires and scales, form to record VS, pharmacy
prescription form, sphygmomanometer and thermometers, etc. It was my function
together with the others SCs to prepare everything in order that when the study
participants arrived for the visit, the persons responsible for performing the procedures
(physicians, psychologists or laboratory technician) had every logistic requirement
available.
One of the important points that we always had to be aware of was if there was a need
for medication in each visit. Prior to the visits in which was scheduled to provide
medication to the study patients, together with the other SCs I had to send to the
pharmacy the request of the necessary study medication according to the protocol. I
was taught how to develop this process by getting the prescription documents from
study files and asking the PI to sign in in order to send it to the pharmacy. This process
shall be performed in an adequate time, so that is guaranteed that no delays happen
with the trial medication delivery to patients. In some studies it was required a
medication request to the IVRS which was normally done by telephone. In order to
keep a good communication with the pharmacy, additionally to formal medication
request in the day before of the visit, every Friday I would send to the pharmacy a
calendar with the schedule of all the visits with medication that would happen in the
CIC.
In some visits there were some procedures such as the infusion of IV medication or the
application of other injectable medication which required the addition of a nurse
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member to the staff. Whenever there was a need for a nurse support I had to
communicate it to the nurse team or individual with antecedence and ensure that
training about the procedures contained in the visit would be provided to the
professional(s).
Every time that according to the study protocol or by investigator’s/sponsor’s indication
a local laboratory exam or any other test in any medical specialty such as neurology,
cardiology or ophthalmology were necessary, I had to request those exams prior to the
study visit.
If any of these activities failed there could be some problems during the patients’ visits
so it was very important to carry this phase of planning and visit preparation with
special seriousness.
3.6.4.2. During the visits
During screening visits, I helped the PI in the Informed Consent Process especially in
the clarification of the CTs specificities to the subjects. Then the physician provided the
medical and scientific information and evaluations required while I was more
responsible with guaranteeing all the requested logistic information that the patients
needed including information about how their transportation from home to the CIC
would be carried, where would he have to go to perform the evaluations that were not
perform inside the CIC and the clarification of how any monetary spending caused by
the participation in the CT would be reimbursed.
During the rest of the study patient participation I assisted in some procedures directly
with the patients. I received training about how to work with an EGC machine and how
these exams are performed and how their results are sent to central reading for a
further clinical report emission. Under other SC supervision I had the chance to perform
these tasks, paraphrasing performing ECGs exams, sending its reports to central
reading and archiving its impressed registries. I also received training in measuring VS
such as blood pressure, pulse, temperature and respiratory rate. Additionally, I assisted
the patients in completing some questionnaires that did not require the presence of a
physician or a psychologist. My assistance was especially useful in helping patients
with disabilities in terms of reading or writing, text comprehension or vision problems.
Having this close contact with the patients allowed me to get more into each study and
its related disease by being able to contact with the patients limitations and needs.
In some of the patients’ visits it was part of the protocol, the collection of biological
samples such as blood and urine to perform after the required laboratory exams. I
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received training on the tasks related with laboratory procedures as stated in the
laboratory manual of each CT. This training was essentially given by the SCs and the
laboratory technician of CIC. I learned and practiced on how to prepare the necessary
kits for each of the study visits and how to handle them. I also got to learn how to work
with a centrifuge and how to process and ship the different samples. Some samples,
normally the ones conditioned at air temperature, were by norm sent in the very same
day of the collection to the lab. Regarding samples condition at negative temperatures,
some of the times were send in the same day but could also be sent in other day
depending on the laboratory protocol indications. When there was a need to keep this
frozen samples we would store them in a refrigerated at a controlled temperature and
at the time of their shipment dry ice and a specific transport box had to be available.
For request the samples shipment we had to phone, e-mail or fax the carrier defined by
the promoter who would pick up them. Additionally we would have to fill a request form
to be sent together with the samples and whenever new materials such as laboratory
kits or transport boxes were needed we had to contact the laboratory for a re-supply of
it.
3.6.4.3. After the visits
After the patients visits I checked if all source documents were signed and dated
properly. Then I would transfer all gathered information from source documents (ex.
Subject clinical file, ECGs, laboratory results, questionnaires, etc.) into the Study CRF.
CRFs exist both in paper or digital format depending on study. With the supervision of
my colleagues SCs I learned how to assess and enter data in the different CRFs, how
to answer queries and on how to make ICH-GCP (5) entry corrections on paper CRFs.
Normally each study uses a different CRF platform and template which implies that we
are familiarized with all kinds of systems. Additionally, I was aware about the
importance of keeping confidentiality on CRFs completions. If an ECG was performed
during the visit I would sent its registry to central lab for evaluation and all material
used had to be archived correctly on the patient’s folder. Checking the CIC stock of
laboratory material was always a must-do task after every visit.
Apart from these activities directly related with the study visits, either with their
preparation, development or data handle, through my internship I can also refer some
other tasks in which I was trained as follows stated below.
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3.6.5. Study closeout visit
After the last CIC included patient in any trial finishes his last visit, the study in
concluded. After this a closeout visit is scheduled between the Sponsor/CRA and
SC/PI. By this appointment all CRFs must be filled and unresolved queries answered.
Prior to this visit, apart from those tasks, I also helped on providing all the info that was
presumed to be necessary as the temperature logs and the signatures of team
members related to their study activity stop dates. The remaining study documents are
kept in the study cabinet until sponsor’s agreement for the archiving of those
documents in the dead archive.
3.6.6. Archiving of CT’s documents
According to the Portuguese law (20), the documents referred as essential shall be
archived for a minimum period of 5 years after the study it’s over. In spite of that,
normally study documents are kept for 15 years due to the instructions of ICH-GCP(5).
During my internship I helped in the archiving of two CTs essential documents. These
documents were sent to the Central Clinical Archive in closed boxes after the study
Sponsor’s agreement.
3.6.7. Permanent contact with CRA
A very important part of the SC’s activity is contacting with the studies promoter or the
Contract Research Associate (CRA) that represent the promoter. Normally that contact
is made through the CRA either by phone and e-mails or by in-site visits. The CRA is
the nominated representative of the interests of the promoter in a CT and so he
monitors the CT ensuring that all the procedures related with the study remain in
compliance with the study protocol and ICH-GCP(5). As a SC trainee I had contact with
CRAs specialty through the training that I had in answering queries, scheduling of
monitoring visits, notification of AE, alert about needing of stock refill and  by providing
and receiving all the documents and information related with the CT.
3.7. The Alnylam Trial
During my internship, included in my training as SC, I got especially involved with some
diseases. My main focus was on Familial Amyloid Polyneuropathy and its related trials.
One of this was a study sponsored by Alnylam called ALN-TTR02-003. In this trial,
ALN-TTR02, a molecule intended for the treatment of Transthyretin-Mediated
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Amyloidosis(ATTR), administered intravenously had the purpose of evaluating safety of
tolerability of its long-term dosing in patients with ATTR who have already been treated
with this investigational product. This is an open-label extension of the trial ALN-
TTR02-002. Participants had to be between 18 and 85 years old, have participated in
the study ALN-TTR02-002 and have an adequate Kamofsky performance status, liver
function and renal function. Being pregnant or nursing in the case of women, having a
liver transplant, having a New York Association heart failure classification bigger than
two or having an unstable angina or uncontrolled cardiac arrhythmia were exclusion
criteria.
Because of my close contribution on the study in the context of my training in study
coordination, the CRO responsible for the trial decided to include me in this CT with the
functions of SC. This gave me a lot more independence, although I always had the
help of Ana Noronha and Maria Finisterra. I was in close contact with all the
intervenient of this CT as is the normal SC task providing all logistical support and
knowledge about the study protocol.
I collaborated together with the colleagues of other study sites and with the study CRA
elaborating a checklist that would help the study staff with each visit procedures. This
was a complex trial in which each visit had a elevated quantity of assessments so this
checklist revealed very important, working as a source document as well as guidance
for the visit line of actions. Additionally I had to prepare the study’s medical
appointments, carry the needed equipment, contact with the CRA either by phone or in
in-site monitoring procedures, contact patients in order to alert them when the day of
the consult was approaching, contact with the pharmacy warning them of the need for
a medication in a specific day, etc. Ultimately, with this CT, I ended up facing my first
official challenge of putting into practise everything that I have learnt in the other
studies
3.8. Other Activities
In addition to my training as a SC I performed other activities during my internship.
Activities that include monitoring, audits, group meetings and pharmacovigilance
training as reported in the following section.
48
3.8.1. European Huntington’s Disease Network (REGISTRY)
At the same time that I was training in study coordination, I got involved since the
beginning of the internship in a prospective cohort study of the REGISTRY. This study
is a multi-center, multi-national OS without experimental treatment being a part of a
worldwide network working towards treatments for HD. The hospital where is physically
located my center of internship, CHLN, E.P.E. – HSM is the Portuguese language
coordinator(34).
Working on this trial at the same time I was trained in Study Coordination and in
Monitoring. Study coordination activities were develop in our site and my tasks were to
prepare visits’ logistics such as  copies of the evaluation scales, either
neuropsychological or motor, labelling  laboratory kits and  preparing samples
shipment. Additionally I distributed questionnaires to patients helping the ones that had
any difficulties in comprehension, reading or writing on them. After the visits I would
have to enter data in the e-CRF and archive all the questionnaires and scales
performed during the visits in the patient file.
Regarding the monitoring activities, conjunctly with my colleague responsible for the
REGISTRY I performed some online and onsite Monitoring visits of the study e-CRF. In
these last, made for ensure the high quality trial conduction. In these visits the following
activities such as reviewing  the ISF and listing what’s missing, checking if ICF’s were
correctly signed and dated,  solving queries in presence of the site team, checking the
source documents and the e-CRF and help the study team when they request it.
After these visits, I had the opportunity to observe my colleague elaborating a
Monitoring Report Site Visit, where a follow-up of the visit is written and included
information such as the number of participants recruited by the center, number of
participants monitored, ICF incomplete and missing, protocol deviations, adherence to
study visit schedule, correction of previous issues pending and queries to be solved.
This report is then sent to the EHDN international coordinator team to be reviewed and
an follow-up e-mail  is also sent, in this case to the visited site to describe what was
done and what shall be done by the site to improve their efficiency and mitigate its
issues.
The process that we did in these centers was also performed by colleagues from Spain
that were the professionals responsible for monitoring CHLN, E.P.E. – HSM. We had to
try to answer to the most possible number of queries online in order to facilitate their
job of online monitoring and reduce the needs of in-site monitoring. When those in-site
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monitoring visits were actually demanding, we prepare the center and the documents
for them to make the entire visit easier either for us in site and for the monitors.
3.8.2. Audit
From April 28th to April 30th, the CIC received an audit related with one of its trial.
Before the audit a CRA was sent by the CRO responsible for that study to together with
the study center staff, prepare the study center in order to receive the auditor. This
auditor was belonging to the study sponsor and had a very meticulous approach to the
study center and to all the study documentation. The objective of the audit was to
check every little detail in the study center or study documentation that was not in
compliance with the study protocol or ICH-GCPs(5). This audit was stress and
laborious to all of the study staff members once we had to intensively prepare the visit
to assure that everything would be ready to receive the auditor and to answer and
provide him anything that he would request. At the end of the visit, a closing meeting
happened where it was discussed the principal findings of the audit by the auditor, the
PI and the rest of the study center staff team.
3.8.3. Journal Club
Once a week, by convention at Wednesday by 8 am, the members of the CIC and the
CPU teams join the CIC “Journal Club”. In these meetings headed by Dr. Miguel
Coelho, members previously chosen present a recent article in the area of neurology
and neurosciences.  After the presentation, there is a little discussion about the study’s
design and findings, its usefulness to clinical research and therapeutics and if a
possible similar investigation could be performed by the center’s team or if between the
study findings some conclusions could be helpful for the CIC team research work.
Apart from this component of articles presentation, these meetings also were useful for
a share of information between the team members about their daily activities and
potential needs for collaboration.
3.8.4. CPU meetings
Most of Wednesdays afternoon was marked by a meeting held on the LCPT. These
meetings allowed team members to present projects in which they were working on.
This was useful in order that all team members were constantly actualized in what each
of us was working on allowing for cooperation and ideas discussion about the already
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in development or potential new projects. These meetings started in mid-November
when all the members of the team introduced themselves and their area of work. This
mutual presentation would reveal very helpful for further cooperative work.
3.8.5. Pharmacovigilance
During the days that I spent in the UFLVT I learnt some procedures that integrate the
functions of a pharmaceutical working in this unit. I learnt how to process the received
spontaneous notifications or AEs to drugs and how to proceed when it comes to follow
up these notifications and close them. I learnt also how alert signs are generated and
why and that a causality imputation is done by a clinician. I had to learn as well during
this time in the UFLVT how the unit quality system is organized by studying their quality
system manual.
3.9. Courses
During the time I was in my internship I had the possibility to attend and receive some
extra training which could help me improving my skills and knowledge in areas such as
ICH-GCP(5), monitoring and entrepreneurship as referred below.
3.9.1. ICH-GCP course
My internship was still on my first month and I already had the notion that the CTs
world was all around ICH-GCP(5) so in On October 1st, 2013, I had the opportunity to
attend a ICH-GCP(5) workshop, headed by Doctor Ingrid Klinman from the
PharmaTrain Initiative at UA. This activity was part of the inauguration session of the
2013 year of the Training Programme in Pharmaceutical Medicine.
In this session it was presented a historical contextualization for the appearance of
ICH-GCP(5), with references to the Nuremberg Code and the Helsinki Declaration, and
the modifications that these guidelines suffered during time. Additionally practical cases
were approached such as patient compliance, requirement of informed consent and the
specific case of minors and other vulnerable people. This was a very interactive
session with space for a lot of discussion in special in themes related with ethical
dilemmas.
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3.9.2. Monitoring Course at Forpoint
On March 23rd I attended a Monitoring Course in CTs in the Perspective of the CRA at
the Keypoint facilities. This training was important to give me a view of what are the
CRA tasks, difficulties and required skills in order to have a better efficiency on working
together with the monitors.
3.9.3. Horizon 2020 Official Opening Session
On 13th December I had the chance to attend to the Horizon 2020 program opening
session. This is a program sponsored by the EU and promotes research and innovation
having for that available a total of 77 billion euros for support to investigation. Attending
this meeting made me aware to the opportunities of financial funding to investigation
and that excellence and entrepreneurship can be supported and rewarded.
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4. Systematic Reviews and Medical Writing
During my internship I got some contact with systematic reviews, especially on which
phases should be considered when planning this kind of investigation, what research
strategies should be followed and which databases can be used for search information
such as PubMed and Medline. Regarding my medical writing activities I had the
possibility to work in three different systematic reviews with the following themes:
 The Study Coordinator activity
 Clinical Trial monitoring – where do we stand? A systematic review
 What can we say about clinical research networks?
These papers appeared after a proposal from Professor Joaquim Ferreira, who
challenged me and my trainee colleagues Marcio Barra and Ana Salgueiro to write a
paper on a matter related to CT.
We decided to collaborate in the elaboration of the three papers. I ended up being the
PI in “The SC activity” paper and a secondary investigator in the other two. More
detailed explanations about the theme of each of the papers are in the sections below.
These three papers are at the moment in a pre-submission phase.
4.1. The Study Coordinator activity
This research theme was chosen due to the increasing of the number of studies by
study site and the higher exigencies of safety and efficacy on CTs what imply that all of
these investigations are very well controlled as well as the study sites where they are
carried. All the procedures must be in compliance with study protocols and ICH-GCP
rules.
This makes very important having a qualified person coordinating the study center in
order to provide an excellent support to experienced and multifaceted teams that can
include physicians, psychologists, physiotherapists, pharmaceuticals, nurses and
statisticians. This has the objective of speeding up most of the processes facilitating
the work of not only all the other members of the study site team but also from other
professionals such as PIs or auditing teams.
This review intended to compile the available information about the legal environment
regulating the CRC position, primary ethical challenges, CRCs’ main activities and
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required skills and the debate of whether the CRC position should be occupied only by
nurses.
4.2. Clinical Trial monitoring – where do we stand? A systematic review
The PI of this paper is Márcio Barra. We decided over this theme because of the
current debate of on-site monitoring versus the newer concept of centralized
monitoring. On-site monitoring is where the CRA is assigned to monitor a clinical or
observational trial in a study centre or group of study centres carrying an in-person
evaluation at the sites. Centralized monitoring is more technology reliant, where the
CRA, or any assigned sponsor personnel, conducts a remote evaluation of the study
centre. Through this investigation is assessed the pro and con of both of the monitoring
strategies
4.3. What can we say about clinical research networks?
The PI of this paper is Ana Salgueiro. This paper surged in the following of the
verification that the current model of research is no longer productive and that the cost-
effectiveness relation is doubtful. Due to that there is a decrease in the development of
innovative therapeutics and an R&D process crisis. Some changes need to take place
among the research community so the attrition rate can be passed and success
reached. One of the strategies is going from small and with lack of communication
groups of investigation to networks of researchers that together can innovate the
process of research, optimize resources and share data. Presently, we can find well-
established and connected clinical research units, named Clinical Research Networks.
In this paper these networks and their strategies for success are reviewed.
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5. Discussion
In order for a new medicine being released to the market it needs to go through a set of
studies to obtain information and evidence on its safety and efficacy. Those studies are
CTs. My internship was mainly focus on CTs and OSs, particularly on its coordination.
Together with the coordination activities I performed other activities, having set a group
of objectives in the early stage of my training that I would like to accomplish during the
time I would spend in this institution.
Since the time I arrived to the centre have already passed 10 months. During this time I
performed several different activities and acquired a relevant combination of knowledge
and experience. What was written in this report cannot rightfully reflect all that I have
passed during my internship due to all the particular moments that have composed it.
What I try is to give a view of the more important things that I retain from this first
contact with the professional environment.
Performing my training in CIC inserted in a hospital as revealed being very profitable
for me because of all the different kind of patients and healthcare professionals that I
have met and contacted with. Since the beginning of the internship, this gave me a
special sensibility regarding how to interact with these different persons depending on
their education, literacy and mental health since is not the same thing to communicate
with a clinician or with an AD patient for example. This kind of personal involvement
gave me a more widespread view of the different persons that I might have to contact
during the internship and prepared me for being a more versatile professional.
The persons working both at CPU, UFLVT and at CIC are all very serious and qualified
professionals, always in a constant effort to perform their work with the best efficiency.
This makes these institutions very successful in their activity. All of these professionals,
including clinicians, SC, statisticians, psychologists, nurses contributed to my training
by always being available to help and guide me whenever I needed.
CIC, which is the institution where I have spent more time, has a team that is very
focused in having increased numbers of patient recruitment while keeping quality of
assistance provided in an high standard. With all this effort is not to wonder the
feedback of satisfaction that is normally received from patients entering in CTs at CIC.
This is very important in CT activity since, concerning ethics, the wellbeing and the
interests of participants are always the main aspect when conducting investigations.
CIC assumes itself has one of the Portuguese centres with the highest recruitment rate
having in opposition a low rate of study withdrawals. Since its formation in 1999,
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sensitively 140 CTs or OBs have already been performed in this centre, demonstrating
its importance in the Portuguese CT frame. It was very positive for me to train at such
well provided and recognized institution.
This numbers express how organized, ambitious and dedicated person working in CIC
really are. Skills like being a good communicator and scientifically precise are some of
the qualities that are shared by all of these professionals. This is fundamental in the
area of clinical investigation since this is a very demanding area especially due to the
entire regulatory framework that surrounds this activity.
Some guidance and ethics documents were already referred in this report including the
Nuremberg Code, the Helsinki Declaration, the ICH-GCPs, Directive 2001/20/CE,
Directive 2005/28/CE and Directive 95/46/CE. These are the basis of CTs regulation
and soon after I arrived to CIC I got in close contact with these. I got an extensive
training on CT ethical consideration in my first weeks of internship. This process was
softened by the fact that during my training I had already have a good background
regarding ethics matters.
My Bachelor in Biomedical Sciences and my first year of MPB were the base for this
internship providing me with knowledge and interest in the area of CTs. This was
fundamental for making me quickly feeling inserted in this environment. I had already
an extensive training on CTs either by knowing their different phases characteristics,
being aware of which are the regulatory authorities and the regulatory literature that are
behind CT framework and knowing how, presently, the investigation investment and
interest looks like in Portugal and in the rest of the world. Out of university and coming
to the internship I also had already some background information about the institution
where I was coming to, but only when I arrived I realized how complex was its structure
and its mission. My luck was the great group that worked with me and explained me
how are divided the different groups of CPU and what activities each one of them
performs.
After having received my early training on guidelines and on the centre’s structure and
mission I was ready to start my training in order to follow the objectives that I set for
this internship.
My primary objective was to receive training as SC. I consider that this objective was
fully accomplished. I was able to develop my knowledge and experience in almost all
the tasks that are delegated to this professional. The most outstanding point that I feel
that I developed were my organization skills. I when arrived to the centre I was not a
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very methodical person and in the first weeks was hard for me to deal with so much
amount of work and responsibilities inherent to the job of SC. As the time was running
by I started to figure out that I had to start to get a method to be able to do all the word
that I had in my charge. So I had to get more organized and plan with time all the
activities that I have for the following days keeping always the ability to deal with not
expected situations. A SC always has to be focus in his activity in order to quickly
detect any fail in the compliance with the running studies protocol and with ICH-GPC.
This constant monitoring is important to prevent major deviations that can lead to
problems regarding the study patients, or the study sponsor. I felt that the background
training from either my Bachelor and Master Degrees were extremely important in
order to develop my training as SC more efficiently and I had the secure feeling that I
applied the knowledge that I already had during this year.
I had contact with several CTs and OSs but the one that marked me the most was the
Alnylam study ALN-TTR02-003 in which I was officially included as a SC. This allowed
me to perform more freely some managing and monitoring activities and was also very
important by becoming the first CT that I could actually include in my curriculum vitae in
spite of having taken an active part in a lot more trials. Regarding these other trial they
were all very important for me, mainly due to its variety of study designs and
procedures, from different sponsors, which challenged me to have to separate in my
mind the different processes in order to all the tasks in compliance with each trial’s
protocol. Among these trials a big set of target disease can be identified. The more
common were PD, AD, FAP, HD, Dystonia, Spasticity, Multiple Sclerosis and Epilepsy.
Having contact with all of these diseases refreshed me my knowledge about such
neurologic pathologies that I had theoretical training about in my Bachelors in
Biomedical Sciences. I felt that my background knowledge was really useful either for
me, either for my colleagues from CIC.
I had to work with a lot of equipment which I did never worked with, such as computer
specific programs for each trial, namely the different e-CRFs platforms, ECG machines
and centrifuges. This was also fascinating for me since I had the opportunity to deal
with some tools that were not of familiar to me and that I had to get used to. Online and
by telephone trainings were also very important helping me using this new tools. These
trainings are obligatory for the intervenient in each trial and apart from teaching how to
work with this equipment also there are trainings that refers to ICH-GCP, biological
samples process and shipment, CTs’ documents archiving and study design and
protocol considerations.
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I also pointed the objective of get in contact with the CIC quotidian, its management
and the activities that there are performed. I was able to realize that in general dealing
with the centre’s CTs and OSs predominate in the healthcare professionals’ daily tasks.
In spite of that, other groups or persons from the CHLN-HSM ´frequently contact with
the CIC personal to ask for information and request for services such has asking for
biological samples collection and shipment, I feel that I developed some managing
skills working on CIC since a SC has to be the glue guy inside a clinical research team,
providing to the other professionals whatever they need to perform their activities. This
is even more highlighted due to the fact that these professionals have so much
different backgrounds and roles inside CIC team.
Having the possibility of working with such a different group of professionals I set the
objective of get some knowledge about their areas in order to make me a better
professional. This was a little bit ambitious since all the activities are pretty different,
specialized and dependent of each one background. In spite of that, I had the chance
to attend to some clinicians consults and treatments, I saw the laboratory technician
collecting biologic samples and nurses performing their nursing activities. I also
contacted with statisticians and medical writer and got some notions about their areas
and what are their tasks and, finally, I was pretty much in touch with the pharmacy
colleagues. This elucidated me of how hard is to manage all the supply, storage and
delivery of medication and all the bureaucratic procedures that are related with their
daily activity.
Before coming into this internship I was in doubt of if I either wanted to have a SC
training or a CRA training. Having the possibility to interact  by several times with CRAs
was very gratifying and useful because I had, as I wanted from the beginning, to
understand what are the CRA’s main activities and what is their overall importance in
the clinical investigation framework. I witnessed how important their hard work is for
keeping the studies protocol compliance and active collaboration with study sites. I got
in really close contact with some CRAs that explained me their day to day tasks, how
much time they spent on central-based monitoring and on in-site monitoring and what
they do on each situation. I had the possibility to put into practise these teachings
about monitoring in the frame of REGISTRY. In this OS apart from the coordination of
the CHLN-HSM centre I monitored together with my colleague responsible for this
study Maria Finisterra, either by web monitoring and by in-site monitoring in the other
Portuguese centres. I can consider that besides study coordination, monitoring
activities were the ones in which I got more prepared in the end of my internship.
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As referred in this report, an audit was performed by a study sponsor to CIC. This was
very useful for my training since I had my first contact with any auditing activity. It was
important for me to understand that even when a research team has the idea that is
doing is job one hundred percent in compliance with study protocol and ICH-GCP there
may always be found some discrepancy and auditing actions are the best situations to
filter those little or major deviations in order to a personal and team improvement.
The time that I spent doing scientific review and writing activities during the last months
of my internship revealed very important to improve my skills in these areas. I got some
train in systematic reviews in my contact with my colleagues at CPU that are
responsible for these investigations and then I was able to put it into practise with the 3
systematic reviews in which I was involved together with my two colleagues trainees
Ana Salgueiro and Márcio Barra. I got to know some processes like the OVID searches
and what strategies to follow ina systematic search frame. Then I got to write about this
reviews and its result is now in a pre-submission process. These activities were very
interesting from scientific and skill enrichment point of view but were not the fields in
which I felt more comfortable and motivated. By a large margin I preferred SC and
monitoring activities.
I also was for some time in touch with the activities performed at UFLVT. This was
really important to have a general knowledge about pharmacovigilance activities
performed in a specialized unit. The processes of adverse events notification reception
and its path until a possible causality imputation were shown and explained to me
although I did not have the possibility to be an active part of this procedure and I limited
to observe. Pharmacovigilance was not and is not my main interest area in what is
related with medicines but I feel that having this more close perspective of the job done
by these colleagues made me a better professional.
The group meetings that we had scheduled every Wednesdays, either the Journal Club
or the CPU meetings, where very important in order to strengthen our team work and
our knowledge about what each of our colleagues was doing. This is a very important
example for me since in my opinion teamwork is the base for any activity, specially a
centre where there is a multidisciplinary team with different backgrounds and interests
where communication is a fundamental point in order to achieve efficiency. Journal
Club was also important in giving me more specific knowledge about Neurology since
recent scientific findings and publications where presented there by the different
members of the team to set the tone for our own team new investigations and to share
new and useful knowledge.
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The trainings that I attended out of my internship environment, namely the ICH-GCP
course, the Monitoring Course at Forpoint and the presence at the Horizon 2020
Official Opening Session where a very good complementary tools for my training since
I could develop my knowledge on GCP guidelines, monitoring procedures and fostering
my entrepreneurship spirit.
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6. Conclusion
Being able to spend my internship in a area that compiles some of my biggest fields of
interest, healthcare and investigational, was very rewarding and useful. Everything that
I’ve learn make this experience unique and I get to the end of this year with the
sensation that almost everything that I have proposed myself in the beginning of this
journey was accomplished.
The place where I trained, CPU, particularly the CIC group made me feel comfortable
from day one, which was one of the cornerstones to making this year become one of
the most enriching ones of my academic life.
I have set some objectives coming to this internship. I received an extensive and
efficient training as a SC as I feel that I accomplished almost completely all the
objectives that I proposed to reach. There are only a few things that I think I could have
done which I didn’t. I would like to have been more in touch with statistician, since I
think that its activity is very important in CT framework. I did not have the enough
availability to spend more time getting to know their work. That happened due to the
really time taking activity that being a SC is. I hope to compensate this low point with
some future training in this area.
The same works with my medical writing skills. I had the possibility to have some
theoretical training and putting it into practise with the revision report that I’ve made
together with my colleagues SC trainee. Although not being my main area of interest I
think is important for my professional future to have more training on my writing skills.
During the internhip and specially looking back at it, I realize how important my
background training was to make easier the adaptation to the professional environment
where I trained.
Working in a teamwork environment was very gratifying since for all my young life I got
used to play in team especially due to my sportsman background. I really liked to fit into
a team where everybody paddles to the same objective of improving investigation and
providing the best treatments and care to patients.
This is very important working in the CT area because our main goal is based on the
belief that our studies and activity will in the future enable better treatments to patients.
Besides working with our team, we also have to collaborate with other professionals
such as the already reffered CRAs. My contact with them was so enriching as I was
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able to watch and learn what are their main functions as I proposed in the beginning of
the internship.
Being in close contact to the patients and witnissing their difficulties, thoughts and
feelings makes us even more compromised with this objective of improving our effort to
reach better treatments and every sign of improvement in these patients are victories
for us.
I retain that as a SC there is an inherent responsibility concerning the CTs conduction
in a clinical site environment. SC are keystones on the development of clinical
investigations. I realized it during my internship since I observed that sites that does not
count with this type of professional cannot keep such high levels of efficiency and
safety when compared with clinical investigation centres is a SC. This happens
because there is a lack of a person that fully dedicates his professional experience to
managing and organizing every tasks and obligations concerning the clinical trials
performed in its site.
In spite of that, a SC is nothing without all the other healthcare professionals that work
inside the clinical site. This way, the most important lesson to keep in my opinion is that
teamwork and a very well balanced and defined tasks delegation based on each
professional knowledge and qualifications is essential. Only this way there is a high
efficiency on the overall provided services of a clinical site.
Looking back I can notice that this was a very profitable experience, that was only
possible thanks to the professionals that collaborated with me and to the background
that I got during my Bachelors and Master’s Degree. Looking into the  future I hope that
I can build up my career in the area of clinical trials as I would like to remain connected
with these activities of study coordination a clinical research monitoring for the next
times.
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